ODYY - Odyssey Health Inc. (ODYY) Drug Product Testing Aims to Give Military Veterans New Weapon for Fighting Brain Injury
- The medical care needs of military personnel are once again in the spotlight following a political dust-up over service members’ exposure to environmental hazards at burn pits
- Another long-standing concern among service personnel is the treatment of concussive brain injuries
- Although no FDA-approved prescription drug currently exists for treating concussions, medical product developer Odyssey Health Inc. is testing a device-drug combination designed to stop concussion injury in its tracks to avoid long-term harm
- Odyssey Health’s product would use an inhaler-like device to deliver the special medication into the nasal cavity for better uptake into the central nervous system, keying on its demonstrated ability to cross the blood-brain barrier
U.S. military service members’ healthcare concerns landed a new place in the spotlight during the past month when outraged veterans and veteran-friendly politicians called attention to a sudden reversal of fortune for a Congressional bill that promised expanded benefits to service members exposed to environmentally hazardous burn pits used in Iraq, Afghanistan, and elsewhere in the years after Sept. 11, 2001.
The bill was slated to label 23 diseases as presumed to be linked to military service, which would have made it easier for veterans to receive expedited health services and disability compensation without having to prove their...
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at http://ibn.fm/ODYY
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text "Biotech" to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.